![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ASH2L |
Gene summary for ASH2L |
![]() |
Gene information | Species | Human | Gene symbol | ASH2L | Gene ID | 9070 |
Gene name | ASH2 like, histone lysine methyltransferase complex subunit | |
Gene Alias | ASH2 | |
Cytomap | 8p11.23 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9UBL3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9070 | ASH2L | PTC05 | Human | Thyroid | PTC | 5.77e-11 | 3.19e-01 | 0.2065 |
9070 | ASH2L | PTC06 | Human | Thyroid | PTC | 9.12e-17 | 2.51e-01 | 0.2057 |
9070 | ASH2L | PTC07 | Human | Thyroid | PTC | 7.93e-18 | 1.88e-01 | 0.2044 |
9070 | ASH2L | ATC12 | Human | Thyroid | ATC | 1.65e-06 | 8.20e-02 | 0.34 |
9070 | ASH2L | ATC13 | Human | Thyroid | ATC | 1.18e-30 | 5.37e-01 | 0.34 |
9070 | ASH2L | ATC2 | Human | Thyroid | ATC | 1.08e-03 | 4.78e-01 | 0.34 |
9070 | ASH2L | ATC4 | Human | Thyroid | ATC | 6.16e-07 | 1.15e-01 | 0.34 |
9070 | ASH2L | ATC5 | Human | Thyroid | ATC | 3.84e-38 | 6.11e-01 | 0.34 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
GO:00165718 | Esophagus | ESCC | histone methylation | 89/8552 | 141/18723 | 2.17e-05 | 1.87e-04 | 89 |
GO:003496814 | Esophagus | ESCC | histone lysine methylation | 72/8552 | 115/18723 | 1.85e-04 | 1.18e-03 | 72 |
GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
GO:00436275 | Esophagus | ESCC | response to estrogen | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:00064797 | Oral cavity | OSCC | protein methylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
GO:00082137 | Oral cavity | OSCC | protein alkylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
GO:00434142 | Oral cavity | OSCC | macromolecule methylation | 149/7305 | 316/18723 | 1.82e-03 | 8.60e-03 | 149 |
GO:00165717 | Oral cavity | OSCC | histone methylation | 72/7305 | 141/18723 | 2.36e-03 | 1.04e-02 | 72 |
GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
GO:00349687 | Oral cavity | OSCC | histone lysine methylation | 58/7305 | 115/18723 | 8.25e-03 | 3.01e-02 | 58 |
GO:001820513 | Oral cavity | LP | peptidyl-lysine modification | 136/4623 | 376/18723 | 3.64e-07 | 1.06e-05 | 136 |
GO:001657014 | Oral cavity | LP | histone modification | 152/4623 | 463/18723 | 4.04e-05 | 5.90e-04 | 152 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASH2L | SNV | Missense_Mutation | c.1849N>A | p.Glu617Lys | p.E617K | Q9UBL3 | protein_coding | deleterious(0.03) | benign(0.152) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ASH2L | SNV | Missense_Mutation | c.553N>A | p.Glu185Lys | p.E185K | Q9UBL3 | protein_coding | tolerated(0.65) | possibly_damaging(0.572) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ASH2L | SNV | Missense_Mutation | rs373871950 | c.1018G>A | p.Gly340Ser | p.G340S | Q9UBL3 | protein_coding | deleterious(0.04) | benign(0.045) | TCGA-A7-A13H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | PD |
ASH2L | SNV | Missense_Mutation | c.1749G>T | p.Lys583Asn | p.K583N | Q9UBL3 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ASH2L | SNV | Missense_Mutation | c.570N>T | p.Met190Ile | p.M190I | Q9UBL3 | protein_coding | tolerated(0.05) | possibly_damaging(0.822) | TCGA-B6-A0RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ASH2L | SNV | Missense_Mutation | novel | c.718C>A | p.Pro240Thr | p.P240T | Q9UBL3 | protein_coding | tolerated(0.23) | probably_damaging(0.994) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ASH2L | SNV | Missense_Mutation | novel | c.1810N>A | p.Glu604Lys | p.E604K | Q9UBL3 | protein_coding | deleterious(0.05) | probably_damaging(0.971) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ASH2L | SNV | Missense_Mutation | c.388N>T | p.Gly130Cys | p.G130C | Q9UBL3 | protein_coding | deleterious(0) | benign(0.325) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ASH2L | SNV | Missense_Mutation | c.1727N>C | p.Ile576Thr | p.I576T | Q9UBL3 | protein_coding | deleterious(0.01) | benign(0.081) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ASH2L | SNV | Missense_Mutation | novel | c.944G>A | p.Arg315Gln | p.R315Q | Q9UBL3 | protein_coding | tolerated(0.09) | benign(0.005) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |